Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,301–2,400 of 3,116
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
Wietholter, J. P., & Terpening, C. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261486055
Falster, M. O., Costa, J. D. O., Milder, T. Y., Carson, J. M., Shadbolt, C., Neuen, B. L., Arnott, C. G., Wilson, A. J., Jun, M., Pratt, N. L., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70715 · Cited by 7
Konservative Adipositastherapie
Kretschmer, A. C., Arjune, S., & Hanßen, R. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01160-6
Adipose Tissue Dysfunction: Clinical Implications and Complications
Dronkers, J., Lobeek, M., Meems, L. M. G., & Gorter, T. M. (2024) · Contemporary Endocrinology · doi:10.1007/978-3-031-72570-8_5
Tipping the Scale Away From Body Mass Index?
Patel, K. V., & Thangada, N. D. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.034
Thinner is better: Intentional weight loss and cardiovascular risk
Abraham, J., Butler, J., & Anker, S. D. (2024) · Med · doi:10.1016/j.medj.2024.01.016
Hundal, J., Linz, M. O., Anikreddy, S., Sengupta, S., Zhou, K., & Maiti, B. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00061 · Cited by 1
Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults
Shah, P., Kayekjian, D., Nguyen, S. A., Meenan, K. D., & O’Rourke, A. K. (2026) · The Laryngoscope · doi:10.1002/lary.70808
Adipositas und kardiovaskuläres Risiko – mehr als nur der BMI
Heinitz, S., & Blüher, M. (2025) · Diabetes aktuell · doi:10.1055/a-2606-7037
Ahmed, A. K. K., & Almutari, K. (2026) · Research Square · doi:10.21203/rs.3.rs-9727771/v1 · Cited by 1
Diabetes as a Risk Factor for Arterial Disease: Management and Prevention
Pavlou, P., Manu, C. A., & EDMONDS, M. E. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_22
Yang, X., & Xie, F. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09349-5
Gifford, R. M. (2026) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvag198
Damman, C. J. (2024) · The Conversation · doi:10.64628/aai.fjd6n4h7t
Cost-effectiveness of the rural lifestyle eating and activity program (Rural LEAP)
Radcliff, T. A., Côté, M. J., Shankar, M. N., Durning, P. E., Ross, K. M., Janicke, D. M., Befort, C. A., Curran, L. S., & Perri, M. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326383
Targeting the cardiohepatic–metabolic axis: GLP‐1–based and incretin multi‐agonist therapies in MASH
Zhang, Y. W., & Hu, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70828
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
“…with established atherosclerotic cardiovascular disease, SE-LECT showed that semaglutide 2.4 mg weekly led to a 20% relative risk reduction in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and nonfatal stroke, compared to placebo [24].”
InfluentialLan, N. S. R., Ali, U., Larbalestier, R. I., Dwivedi, G., & Fegan, P. G. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2024.02.001
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“This finding provided the first large-scale evidence supporting the cardiovascular benefit of an anti-obesity pharmaco-therapy in a non-diabetic cohort [73–75].”
Reducing Cardiovascular Disease Risk in Obesity
Abushamat, L. A., Hamid, A., Nambi, V., Wu, H., & Ballantyne, C. M. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.019
Incretin analogues as cardiovascular agents: a state-of-the-art review
Garaygordobil, D. A., Rico-Fontalvo, J. E., Hernández-Balbuena, B., Vinay, M., & Gonzalez-Arias, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1898812 · Cited by 1
“%) is one of the largest reported with any cardiometabolic drug class, and it correlates only loosely with weight loss (9, 14, 28).”
Tratamiento de la angina estable
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Álvarez, D. I., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.003
Melnikov, I., Borodko, D. D., & Alekseev, V. (2026) · Cells · doi:10.3390/cells15171578
“Furthermore, the MACEs curves began to separate relatively early during the treatment period, suggesting that the cardiovascular benefit may not be explained solely by the extent of weight loss [6,9].”
InfluentialSmith, C. R. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000055
Król, M., Woźniak, A., Straszewska, A., Sobantka, P., Mokrzecki, S., Mamach, A., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6208
GLP-1 receptor agonists in obesity treatment: where we are today and what can we expect?
Pichlerová, D. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.070
Pharmacotherapeutic Strategies to Prevent Progression to ESKD and Reduce Cardiovascular Risk
Odutayo, A., & Cherney, D. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00222024 · Cited by 1
Sami, M. M., Zahid, I., & Latif, M. B. (2026) · Internal Medicine Journal · doi:10.1111/imj.70387
GLP-1 receptor agonists: panacea or affirmation of societal failure?
Kallis, T. J., & Payne, R. (2025) · British Journal of General Practice · doi:10.3399/bjgp25x741069
Huh, K. Y., & Song, I. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351415 · Cited by 1
“The cardiovascular benefits of GLP-1 RAs have expanded beyond populations with diabetes, as evidenced by the SELECT trial showing a 20% reduction in major adverse cardiovascular events among patients with obesity without diabetes [3].”
A Precision Medicine Approach for Obesity Management
Añazco, D., Feris, F., Fansa, S., Espinosa, M. A., & Acosta, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_15
Ahmed, Z., Mustafa, N., Sarkar, T., & Yasmin, H. (2026) · Health Science Reports · doi:10.1002/hsr2.73044
A Sex-specific Mendelian Randomization-Phenome-Wide Association Study of Body Mass IndexPreprint
Jiesisibieke, Z. L., Chan, I. I., Ng, J. C. M., & Schooling, C. M. (2025) · eLife · doi:10.7554/elife.102573.2
Siddiqui, S. I., Tabatabaie, V., & Aleksić, S. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag010
Cardiovascular-kidney-metabolic-syndrome: a modern view of the problem
Кanorskiy, S. G. (2025) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2025-6-3-6-16
Liu, Z., Fourlanos, S., & Chong, E. W. T. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.05.018
Akinmolayemi, O., Oliva, A., Sartori, S., Vasa, D., Feng, Y., Sweeny, J. M., Hooda, A., Bhatt, D. L., Dangas, G., Mehran, R., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.05.044
GLP-1 receptor agonists after liver transplant: Early reassurance, unanswered questions
Albhaisi, S. A. M., Spagnoli, J., & Sharma, P. (2026) · Liver Transplantation · doi:10.1097/lvt.0000000000000978
Cardio‑Reno‑Metabolic Syndrome: A Decade of Evidence (2014–2024)
Duranti, E. (2026) · Journal of Cardiology and Cardiovascular Medicine · doi:10.29328/journal.jccm.1001223
Research Note: A Novel Sullivan Method Projection Framework With Application to Long COVID
Ryan-Claytor, C., & Verdery, A. M. (2024) · Demography · doi:10.1215/00703370-11226858 · Cited by 1
Secondary Prevention in Older Adults
Park, J. K., Ugoala, O. S., Ebubechukwu, U. J., & Agarwala, A. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.008 · Cited by 1
Ramirez, A., Rogerson, L., Kyzar, E. J., Berland, C., Rodriguez, E., Guerrero, J., Hammond, L. A., Ferrante, A. W., & Salzman, C. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.07.641687
Les meilleures études en 2023 adaptées aux soins primaires
Thomas, B. S., Perry, D., Moe, S. S., et al. (2024) · Canadian Family Physician · doi:10.46747/cfp.7004e47
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Bellini, D., Lloyd, A. B., Leicht, C. A., Hodder, S., & Maley, M. J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0353797
“Moreover, despite recent breakthroughs in pharmacological treatments of obesity, T2DM and CVD outcomes (e.g., GLP-1 receptor agonists) [5,6], the financial burden associated with NCDs continues to rise, reaching more than $500 billion annually in Europe alone [7].”
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Smirnova, E., Siddiqui, M. S., Wilson, L., & Sanyal, A. J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5797107
Kudaiberdieva, G. (2023) · Heart Vessels and Transplantation · doi:10.24969/hvt.2023.441
Exploring Additional Cardiorenal Outcomes—Beyond the Primary Composite End Point
Fonarow, G. C., & McMurray, J. J. V. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0780
Tirzepatide and semaglutide: different twins?
Cesaro, A., Acerbo, V., & Calabrò, P. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag028
Weight management in cardiology practice: challenges and opportunities
Leening, M. J. G., Martens, F. M. A. C., & Hemels, M. E. W. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02075-1
“In the SELECT trial, high-dose semaglutide was generally well tolerated, yet one in ten participants discontinued semaglutide because of gastrointestinal intolerance, and in total one in six participants discontinued medication during a median follow-up of 3 years [13].”
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
Medikamentöse Strategien bei chronischem Koronarsyndrom – nach Koronarintervention und bei INOCA
Hochholzer, W. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2530-3370
Vercalsteren, E., Mazya, M. V., Nyström, T., Darsalia, V., & Patrone, C. (2026) · BMC Medicine · doi:10.1186/s12916-026-04809-9
“Indeed, GLP-1RA can reduce CVD risk in obese individuals both with and without T2D (SUS-TAIN-6 study [40], SELECT trial [41]).”
Diversity of pleiotropic effects of semaglutide: From potential mechanisms to real clinical outcomes
Demidova, T. Y., Izmaylova, M. Y., & Shirnina, M. E. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-1-03
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
“) [66] and reduced CKD progression (FLOW trial) [67 ], supporting its role as a first-line therapy in patients with MASLD and cardiometabolic disease.”
Sanyal, A. J., Parmar, K., de Oliveira, A. B. S., Jahagirdar, V., & Smirnova, E. (2026) · Research Square · doi:10.21203/rs.3.rs-8342646/v1
Rivero-Moreno, Y., Estrada, A., Zamata-Ovalle, D., Hindosh, N., Oviedo, R. J., Choi, J., Moran-Atkin, E., & Camacho, D. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08627-z
“Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, induce weight loss and reduce death for cardiovascular disease, but require ongoing treat - ment, with weight regain common after discontinuation [7].”
Mokrzecki, S., Mamach, A., Bełc, E., Brzezińska, K., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Król, M., Straszewska, A., Woźniak, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6230
Brogaard, E., Nielsen, V. W., Pedersen, N. H., & Thomsen, S. F. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2738341
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
“HbA1c decreased by 0.31%, despite the absence of diabetes at baseline, and both systolic and diastolic blood pressure were reduced [29].”
InfluentialTirzepatide for OSA and obesity: do we know the effect on cardiometabolic outcome?
Bloomgarden, Z. T. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.115
Khalil, I., Sarker, P., Hossain, M. S., Chowdhury, A., Khalid, A. A., Saha, A., Chowdhury, J., Akter, M. M., Promi, S. A., Sayed, M. A., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.004
Wiencke, K., Zimmermann, R., Gentz, A., Clever, S., Oddsson, S. J., Hasenberg, T., Arnar, D. O., & Grannell, A. (2026) · Obesities · doi:10.3390/obesities6040051
“GLP-1 receptor agonists such as semaglutide 1.0 mg and 2.4 mg have been shown to reduce morbidity and mortality in patients at risk of CV events [16,17].”
InfluentialDuun, O. M., Dichman, M.-L., Lindschou, J., Scragg, J., Petersen, J. J., Bojsen-Møller, K. N., Jebb, S. A., Gluud, C., & Dirksen, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-111336
“23 GLP- 1-RAs are already being combined with other gut hormones to enhance long-term weight loss, most recently in tirzepatide, which combines GLP- 1-RA with gastric inhibitory polypeptide.”
Raptis, D., Nazarenko, N., Agarwal, R., Shah, M. K., Gao, Y., Theodoropoulos, P., Borkowski, P., Maliha, M., Policarpio, M. A., Yakkali, S., et al. (2026) · Diabetology · doi:10.3390/diabetology7080155
BERBERINE IN METABOLIC DISORDERS: THE “NATURE’S OZEMPIC” PHENOMENON - A NARRATIVE REVIEW
Lenkiewicz, E., Maciejewska, A., Stepinska, M., Omiecińska, M., Kaczor, M., Trynkiewicz, W., Rybka, Z., Żak, J., Dąbrowska, K., & Winiarczyk, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5247
Chen, G., Lan, Y., Wu, D., Liu, P., Zheng, H., Wang, Y., Chen, Y., & Chen, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1901020 · Cited by 1
“In parallel, pharmacological therapies aimed at improving insulin resistance and metabolic status, including certain glucose-lowering and met-abolic-modulating agents, have been associated with favorable cardiovascular outcomes (36, 37).”
Zheng, C., Muir, K. C., Reddy, R., Stone, C. R., Harris, D. D., & Sellke, F. W. (2026) · Surgery · doi:10.1016/j.surg.2026.110369
Kim, E. Y., & Feinstein, M. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.024 · Cited by 5
Extending the Reach of GLP-1 Receptor Agonists for Cardiovascular Risk Reduction
Lincoff, A. M. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5106
Self-citationGao, A., Peng, B., Gao, Y., Yang, Z., Li, Z., Guo, T., Qiu, H., & Gao, R. (2024) · Research Square · doi:10.21203/rs.3.rs-4277196/v1
GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension
Al‐Ali, D., & Hajj, N. E. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113325
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Asadullin, A. R. (2026) · Neurology Bulletin · doi:10.17816/nb707354
Effect of Submaximal-Dose Semaglutide on MASLD Biopsy-Free Scoring Systems in Patients with Obesity
Focko, B., Péč, M. J., Miertová, Z., Jurica, J., Miert, A., Kubikova, L., Tudík, P., Nagy, N., Lecký, P., Ságová, I., et al. (2026) · Livers · doi:10.3390/livers6010003
“Recently, there have been the first reports regarding a possible positive effect of GLP-1RA therapy on MASLD progression [12–14].”
Weekly Journal Scan: REDEFINing the next generation of obesity pharmacotherapy
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf628
Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
Al-Nusair, M., Khurana, S., Eysha, M., Elchouemi, M., & Zaki, I. H. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02087-z
The Role of GLP-1R and GIPR Agonism in Heart Failure
Sedrak, P., & Connelly, K. A. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3138 · Cited by 1
Choi, H., & Hwang, A. Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70903
Jain, H., Soni, K., Patel, N., et al. (2026) · CJC Open · doi:10.1016/j.cjco.2026.07.008
Metabolic syndrome and heart failure
Lopatin, Y. M. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6540 · Cited by 1
Khan, M. M., Imam, H., Mondal, N. T., et al. (2025) · TAJ Journal of Teachers Association · doi:10.70818/taj.v38i04.0887
Semaglutide’s dilemma: A lifesaver with a price?
Dingal, N. S. (2025) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_19_25
Jiang, W., Fukunaga, K., Kobayashi, T., Saheki, T., Yoshimura, T., Zhang, H., Ly, R., Imachi, H., & Murao, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188378
“GLP-1 receptor agonists produce clinically established reductions in body weight, glycemic exposure, and cardiovascular risk, and selected agents also improve organ-level outcomes relevant to lipid overload [5,6,43,55,56].”
InfluentialImplications of GLP-1 RA Therapy on Skeletal Health and Orthopedics: A Commentary
Gertzulin, M., & Drake, M. T. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261450988
Therapie metabolischer Lebererkrankungen: Lebensstilintervention, Chirurgie und Pharmakotherapie
Huttasch, M., & KAHL, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01502-6
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01446-x
Andò, G., Cavolina, G., Villari, A., Sabouret, P. F., & Musumeci, G. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133058
Traitements médicamenteux par agonistes des récepteurs au GLP1 et obésité de l’adulte
Carette, C., Phan, A., & Czernichow, S. (2025) · Soins · doi:10.1016/j.soin.2025.05.020
Omidi, F., Nasiri, M. J., & Sadeghi, S. (2024) · Advances in Medicine · doi:10.1155/2024/7038875
Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Cheng, C., Tang, M., 张兆波, Qu, R., Pei, J., Liu, T., Qu, S., You, S., Cui, S., Wang, W., et al. (2026) · Advanced Science · doi:10.1002/advs.77260 · Cited by 1
“Glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular events with approximately two-thirds of protection occurring independently of adiposity reduction [ 158, 160 ].”
Tsai, Y., Lin, H.-T., Liu, Y.-F., Chang, R., & Wu, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s612622
Immunology of Cardiometabolic Health and Disease: From Novelty to Necessity
DAY, E. D., Dick, S. A., Epelman, S., Dobrev, D., & Feinstein, M. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.06.005
He, J., Wei, J., Wang, B., Ru-fei, L., Wang, W., & Li, Y. (2026) · Biomolecules · doi:10.3390/biom16070989 · Cited by 1
“…receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, such as semaglutide and tirzepatide, have recently attracted considerable attention because of their effects on body weight, glucose metabolism and cardiovascular outcomes [10].”
Alves, M. L. M., Costa, A. O. D. S. M., Costa, J. D. V. M., Garrido, G. A., Gonzalez, J. V. P., Ferreira, J. S. N., & Pereira, B. D. A. (2026) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2026.100938
“JSNF : Nothing to disclose, BDAP : Nothing to disclose. sity and established cardiovascular disease [ 2–4 ].”
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
